EXPRESSION AND FUNCTION OF APOPTOSIS-REGULATORY PROTEINS IN B-CLL. B-cell chronic lymphocytic leukemia (B-CLL) represents a human neoplastic disorder which arises primarily because of failures in the normal mechanisms for cell turnover through programmed cell death, rather than as a result of alterations in cell cycle regulation. Genetic alterations that inhibit normal programmed cell death can render tumor cells more resistant to apoptosis induction by anti-cancer drugs. Previous studies have documented abnormalities in the expression of certain Bcl-2 family proteins in B-CLLs. This family of proteins plays a critical role in controlling cellular responses to apoptotic stimuli, including those induced by essentially all chemotherapeutic drugs. The central hypothesis to be tested in this proposal is that alterations in the expression or function of apoptosis/regulatory proteins represents a critical obstacle to successfully treating B-CLL. Among the questions that will be addressed during the testing of this hypothesis are: (1) Do differences in the expression or phosphorylation states of Bcl-2-, IAP-, caspase-family proteins explain why some B-CLL patients achieve complete responses (CR) to chemotherapy while others do not (NR; PR)?; (2) How do purine nucleosides used in the treatment of B-CLL affect the expression or function of these apoptosis-regulatory proteins, and do interactions of these compounds with Apaf-1 or mitochondria (as opposed to DNA damage) account for variations in clinical responses? (3) Can kinase modulatory drugs, cytokines, or anti-B-cell monoclonal antibodies be employed in vitro for modulating the expression or function of apoptosis-regulatory proteins, thus rendering B-CLLs more sensitive to conventional chemotherapeutic drugs? The results of these investigations are anticipated to improve understanding of the relation between defective apoptosis mechanisms in B-CLL and responses to therapy, and thus may generate strategies for improving the treatment of B-CLL patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081534-03
Application #
6474078
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-07-11
Project End
2002-04-30
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510
Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970
Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39
Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600
Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7
Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438
Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736

Showing the most recent 10 out of 562 publications